Oruka Therapeutics Inc
ORKA
查看详细走势图
32.120USD
+0.410+1.29%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.55B总市值
46.19市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.29%
5天
+13.18%
1月
+7.53%
6月
+173.13%
今年开始到现在
+65.65%
1年
+52.01%
查看详细走势图
TradingKey Oruka Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Oruka Therapeutics Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名90/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价46.82。中期看，股价处于上升通道。近一个月，市场表现较强，技术面评分较高，但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Oruka Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
12
位分析师
强力买入
评级
46.818
目标均价
+48.89%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Oruka Therapeutics Inc亮点
亮点风险
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值46.19，处于3年历史高位
机构加仓
最新机构持股38.19M股，环比增加3.51%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值584.39K
Oruka Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Oruka Therapeutics Inc简介
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
公司代码ORKA
公司Oruka Therapeutics Inc
CEOKlein (Lawrence Otto)
网址https://orukatx.com/
常见问题
Oruka Therapeutics Inc(ORKA)的当前股价是多少？
Oruka Therapeutics Inc(ORKA)的当前股价是 32.120。
Oruka Therapeutics Inc的股票代码是什么？
Oruka Therapeutics Inc的股票代码是ORKA。
Oruka Therapeutics Inc股票的52周最高点是多少？
Oruka Therapeutics Inc股票的52周最高点是32.640。
Oruka Therapeutics Inc股票的52周最低点是多少？
Oruka Therapeutics Inc股票的52周最低点是5.485。
Oruka Therapeutics Inc的市值是多少？
Oruka Therapeutics Inc的市值是1.55B。
Oruka Therapeutics Inc的净利润是多少？
Oruka Therapeutics Inc的净利润为-83.72M。
现在Oruka Therapeutics Inc(ORKA)的股票是买入、持有还是卖出？
根据分析师评级，Oruka Therapeutics Inc(ORKA)的总体评级为--，目标价格为46.818。
Oruka Therapeutics Inc(ORKA)股票的每股收益（EPS TTM）是多少
Oruka Therapeutics Inc(ORKA)股票的每股收益（EPS TTM）是0.695。
相关品种
